Home > Expanded Access > An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine

Biohaven Pharmaceuticals, Inc.

An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine

Official Title: 
BHV3000-401: An Open-label, Intermediate-size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine
Brief Summary: 
The purpose of this protocol is to allow subjects who completed any BHV3000 (rimegepant) clinical study to continue to have access to rimegepant while collecting ongoing safety data.
Available
EA Type
Treatment IND/Protocol
Migraine

Drug: rimegepant
rimegepant 75 mg

Eligibility Criteria: 

Inclusion Criteria:

1.Subjects who have completed any BHV3000 (rimegepant) clinical study without significant
protocol violations.

Exclusion Criteria:

1. History of basilar migraine or hemiplegic migraine

2. History with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease

3. HIV history

4. Uncontrolled hypertension or uncontrolled diabetes

5. Current diagnosis of major depression, other pain syndromes, psychiatric conditions (e.g., schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments

6. History of gastric, or small intestinal surgery, or has a disease that causes malabsorption

Eligibility Gender: 
All
Eligibility Age: 
Minimum: 18 Years
Contacts: 

Early Access Care
203-779-8501
ExpandedAccess@EarlyAccessCare.com

Biohaven Pharmaceuticals, Inc.
EA Number: 
Keywords: 
Migraine prevention, phonophobia, photophobia, nausea
MeSH Terms: 
Migraine Disorders
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.